Journal
SCIENCE
Volume 341, Issue 6148, Pages 865-U71Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1233151
Keywords
-
Categories
Funding
- Fondazione Telethon (TIGET)
- European Commission [CLINIGENE LSHB-CT2006-018933, CELL-PID HEALTH-F5-2010-261387, GA 222878 PERSIST, 249845]
- Ministero della Salute (Ricerca Finalizzata) [005/RF-2009-1485896]
- Ministero della Salute (Progetto Giovani Ricercatori) [GR-2007-684057]
Ask authors/readers for more resources
Wiskott-Aldrich syndrome (WAS) is an inherited immunodeficiency caused by mutations in the gene encoding WASP, a protein regulating the cytoskeleton. Hematopoietic stem/progenitor cell (HSPC) transplants can be curative, but, when matched donors are unavailable, infusion of autologous HSPCs modified ex vivo by gene therapy is an alternative approach. We used a lentiviral vector encoding functional WASP to genetically correct HSPCs from three WAS patients and reinfused the cells after a reduced-intensity conditioning regimen. All three patients showed stable engraftment of WASP-expressing cells and improvements in platelet counts, immune functions, and clinical scores. Vector integration analyses revealed highly polyclonal and multilineage haematopoiesis resulting from the gene-corrected HSPCs. Lentiviral gene therapy did not induce selection of integrations near oncogenes, and no aberrant clonal expansion was observed after 20 to 32 months. Although extended clinical observation is required to establish long-term safety, lentiviral gene therapy represents a promising treatment for WAS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available